Epoetin (erythropoietin)
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Epoetin (erythropoietin) and local guidelines before prescribing.
Erythropoiesis-stimulating agent
Mechanism
Recombinant erythropoietin stimulating red cell production.
Uses
Anaemia of CKD, chemotherapy anaemia.
Dosing
- Epoetin / darbepoetin | Target Hb 100–120 g/L; hypertension, thrombosis, stroke if overcorrected.
Renal: Anatomy, Physiology and Pharmacology - ESA (epoetin, darbepoetin) | Target Hb 100–120 g/L; higher targets cause stroke and thrombosis; hypertension.
Renal: Chronic Kidney Disease - 3. A man on haemodialysis has Hb 89 g/L despite epoetin. Ferritin 80, TSAT 12%. Answer: ESA resistance from iron deficiency.
Renal: Chronic Kidney Disease - Then erythropoiesis-stimulating agents (e.g. epoetin, darbepoetin) with a Hb target of about 100–120 g/L .
Haematology: Anaemia
1 more dose entries from the chapters
- Epoetin / darbepoetin | Anaemia of CKD after iron replete; Hb target about 100–120 g/L; hypertension, thrombosis.
Haematology: Anaemia
Side effects
Hypertension, thromboembolism, pure red cell aplasia, headache.
Interactions
Few.
Contraindications and cautions
Uncontrolled hypertension
Monitoring
Hb, ferritin, BP
Pregnancy and breastfeeding
Acceptable
Renal and hepatic impairment
No adjustment
Overdose and reversal
Venesection
Special advice
Ensure iron replete before starting; target Hb limit to avoid thrombosis.
More from the textbook: uses, cautions and other points
- Erythropoietin | Interstitial cells of the cortex, in response to low oxygen (HIF pathway) | Deficiency → normocytic anaemia of CKD (usually once eGFR is under about 30); excess → polycythaemia (kidney cancer, cysts, after transplant)
Renal: Anatomy, Physiology and Pharmacology - Anaemia of CKD - mainly erythropoietin deficiency , plus iron deficiency (blood loss, poor absorption, high hepcidin) and inflammation; check for other causes first (B12, folate, bleeding, haemolysis, myeloma).
Renal: Anatomy, Physiology and Pharmacology - Less erythropoietin (EPO) made by the kidney.
Renal: Chronic Kidney Disease - Hb 135 on epoetin with new hypertension | ESA overtreatment - reduce the dose
Renal: Chronic Kidney Disease - Growth factors control production - erythropoietin (kidney - red cells), thrombopoietin (liver - platelets), G-CSF (neutrophils), interleukins. Several are given as drugs.
Haematology: Anatomy Physiology and Pharmacology - Making red cells needs - erythropoietin (kidney), iron (haemoglobin), vitamin B12 and folate (DNA synthesis - deficiency causes large, immature "megaloblastic" cells), plus vitamin B6, copper, thyroid hormone and androgens.
Haematology: Anatomy Physiology and Pharmacology - Reduced erythropoietin , plus iron deficiency and inflammation.
Haematology: Anaemia - Treat anaemia early ( IV iron , B12, folate, erythropoietin).
Haematology: Haemoglobinopathies and Transfusion
Where it is discussed in the book
- Renal: Anatomy, Physiology and Pharmacology (3 mentions)
- Renal: Chronic Kidney Disease (4 mentions)
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Anaemia (3 mentions)
- Haematology: Haemoglobinopathies and Transfusion (1 mention)
- Haematology: Myeloma and Lymphoma (1 mention)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (1 mention)
- Biochemistry: Clinical biochemistry - interpreting laboratory tests (1 mention)
- 0231 (1 mention)
- 0286-gastrointestinal-haematological-reproductive-and-integrative-ph (1 mention)